MedTrace Logo

FMISO-based Adaptive Radiotherapy for Head and Neck Cancer

NCT05348486 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-04-22

No results posted yet for this study

Summary

Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET/CT. Moreover, hypoxic subvolumes of tumors can be evolving as target volumes for radiotherapy ("dose painting") in hypoxia imaging-based dose escalation.

Conditions

Interventions

RADIATION

Dose escalation

Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN \> 2cm

Sponsors & Collaborators

  • Masaryk Memorial Cancer Institute

    collaborator OTHER

  • University Hospital Ostrava

    collaborator OTHER

  • University Hospital Olomouc

    lead OTHER

Principal Investigators

  • Martin Dolezel, Prof. · Palacký University and University Hospital Olomouc

  • Marek Slavik, Ph.D. · The Masaryk Memorial Cancer Institute (MMCI)

  • Jakub Cvek, Prof. · Faculty Hospital Ostrava

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-20
Primary Completion
2025-06-30
Completion
2030-06-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05348486 on ClinicalTrials.gov